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Abstract
Background: Mutations in the nucleophosmin (NPM1) gene have been solely associated with childhood acute
myeloid leukemia (AML). We evaluated the frequency of NPM1 mutations in childhood AML, their relation to
clinical and cytogenetic features and the presence of common FLT3 and RAS mutations.
Results: NPM1 mutations were found in 8% of cases. They involved the typical type ‘A’ mutation and one novel
mutation characterized by two individual base pair substitutions, which resulted in 2 amino acid changes (W290)
and (S293) in the NPM protein. FLT3/ITD mutations were observed in 12% of the cases and in one NPM1-mutated
case bearing also t(8;21) (q22;q22). No common RAS mutations were identified.
Conclusions: A relatively consistent NPM1 mutation rate was observed, but with variations in types of mutations.
The role of different types of NPM1 mutations, either individually or in the presence of other common gene
mutations may be essential for childhood AML prognosis.
Background
Acute myeloid leukemia (AML) is a genetically and phe-
notypically heterogenous disease that accounts for 15-20%
of childhood leukemia [1]. Several genetic mutations, gene
rearrangements and chromosomal translocations are
involved in the pathogenesis of leukemia. Chromosomal
abnormalities like the t(15;17) or the inv(16) have been
associated with a particular morphology and clinical beha-
vior [2]. However, in patients with no detectable chromo-
somal abnormalities, the genetic background remains
unknown [3,4]. Conversely, previous work has indicated
the involvement of various gene mutations with prognostic
relevance in AML, including activating mutations of genes
encoding transcription factors (AML1, CEBPa), tyrosine
kinases (FLT3, KIT) or their downstream effectors (NRAS)
and nucleophosmin (NPM1)m u t a t i o n s[ 3 , 5 ] .
Nucleophosmin is a multifunctional nucleocytoplasmic
protein involved in several cellular activities, such as
ribosomal biosynthesis, maintenance of genome stability
and molecular chaperone functions [6,7]. Abnormal
expression of NPM may lead to the oncogenesis of some
types of leukemia as NPM1 gene is a partner in several
tumor associated chromosomal translocations [5].
A number of studies have described the presence of com-
mon mutations within the final exon (exon-12) of the
NPM1 gene in patients with AML [1,5,7-11]. These
mutations cause the cytoplasmic localization of NPM
and abrogate its function [12].
NPM1 gene mutations have been described in both
adult and pediatric patients with variable prevalence and
proven to have prognostic significance. NPM1 is mutated
in a large proportion (30-50%) of adult AML cases with a
normal karyotype [8,13]. This subset of AML patients
that exhibit a normal karyotype account for approxi-
mately 50% of cases and thus far have a markedly variable
outcome. The NPM1 mutations in AML cases with a
normal karyotype have been significantly associated with
high frequency of internal tandem duplications of FMS-
like tyrosine kinase-3 (FLT3/ITD) [1], which are consid-
ered to confer a less favorable prognosis.
The current study was undertaken to evaluate the pre-
valence of NPM1 mutations in childhood AML in asso-
ciation with cytogenetic analysis, molecular screening of
common gene mutations and patients’ clinical character-
istics, in order to address its prognostic relevance.
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Patient Samples
A total of 28 pediatric patients were diagnosed with AML
within a 10-year period. The patient population comprised
primarily of Greek children (24/28), whilst the rest of the
cohort included Albanian (3/28) and Romanian (1/28)
patients. All patients received chemotherapy according to
BFM AML protocol (BFM87; n = 14 and BFM04; n = 11)
for 12 months. Patient samples were obtained from bone
marrow aspirates at diagnosis. Sufficient amount of DNA
for analysis of NPM1 mutations was available in 25/28
(89.3%) patients at diagnosis. Of those, 18/25 were diag-
nosed with de novo AML and 7/25 with secondary AML
following myelodysplastic syndrome (MDS). The patients’
median age was 7 years (range 1-14 years) and among
them, 12/28 (48%) patients were male. The diagnosis was
based on the French-American-British (FAB) classification
scheme and immunophenotype. The study population
included 1 patient with M0, 4 patients with M1, 4 patients
with M2, 3 patients with M4, 5 patients with M5 (4M5a
and 1M5b) and 1 patient with M6 FAB subtype. This
study was approved by the Medical School of the Univer-
sity of Athens in Greece.
Cytogenetic analysis
Cytogenetic investigations were performed by karyotyp-
ing G-banding analysis in all patients. Additionally,
interphase fluorescence in situ hybridization (iFISH) was
used to monitor chromosomal aberrations.
Molecular analyses of NPM1, FLT3 and RAS mutations
Genomic DNA was extracted from bone marrow samples
according to the standard phenol-chloroform protocol.
The exon 12 of the NPM1 gene was amplified using poly-
merase chain reaction (PCR). The primers and the proce-
dure were adapted from Döhner et al.[ 1 4 ] .M u t a t i o n a l
analyses of the FLT3/AL (activation loop) at positions
D835/I836, FLT3/ITD and RAS genes (NRAS, HRAS and
KRAS) were performed as previously described [15].
DNA sequencing
Direct sequencing of both strands of each PCR product
was carried out on an ABI PRISM 3100-Avant Genetic
Analyser (Applied Biosystems, Foster City, CA),
according to the manufacturer’s instructions. All sam-
ples were sequenced, including those that did not pro-
vide preliminary evidence for FLT3 mutations based
on electrophoresis.
Statistical analyses
T h ep r e v a l e n c eo fNPM1 mutations in AML was too
low to permit statistical analysis for correlation with sur-
vival. Actuarial estimates of the event-free-survival (EFS)
and overall survival (OS) at 5-years were calculated for
20/25 patients (5/25 newly diagnosed) using the Kaplan-
Meier method. Event-free-survival is defined as the time
from randomisation to treatment failure (relapse, second
malignancy or remission failure) or death. Overall survi-
val denotes the percentage of patients survived for a cer-
tain period of time since diagnosis or treatment
completion. Statistical significance between NPM1-wild
type and NPM1-mutated groups with clinical and cyto-
genetic characteristics was determined by Fischer’s exact
test.
Results
Patients Characteristics
The laboratory and clinical characteristics between the
NPM1-mutated group and the NPM1-wild type group
of patients were compared. The NPM1 mutations were
present in patients with AML M1 and M2 FAB sub-
types. There was no significant difference in the preva-
lence of NPM1 mutations between sexes. In addition,
the mutations were not particularly associated with
higher white blood cell count (WBC) or increased blast
percentage. However, there was a significant difference
with regard to age. Τhe median age in NPM1-mutated
group was 10.5 years and in NPM1-unmutated group
was 6.5 years (p = < 0.001). The study of possible ethnic
differences related to the disease was not feasible, due to
limited number of patients.
Cytogenetic analysis
In this study, chromosomal aberrations were observed in
12/25 (48%) cases. In 4/12 (33.3%) patients t(8;21) (q22;
q22) was detected, which was principally associated with
the AML M2 FAB subtype (75%). This chromosomal
abnormality occurred predominantly in children older
than 3 years of age (18.2%) and in 16% of the whole AML
population. MLL gene rearrangements with chromosome
11q23 abnormality were detected in 3/12 (25%) cases;
one AML M4 and one M5 newly diagnosed patient with
t(9;11)(p22;q23) and one M4 with t(6;11)(q27;q23). The
MLL gene rearrangements were more common in chil-
dren younger than 3 years of age (2/3, 66.7%). No NPM1
mutations were found in cases with positive MLL gene
rearrangements.
Molecular analysis of gene mutations
NPM1 gene mutations were detected in 2/25 (8%)
patients with AML (2/18 patients were de novo AML;
one M1 AML and one M2 AML newly diagnosed). One
of the NPM1 mutations involved multiple base pair sub-
stitutions rather than the common 4 base pair inser-
tions. More specifically, the patient acquired a T®G
mutation at codon 290, which resulted in a substitution
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tion at codon 293, which resulted in a substitution of
serine 293 for proline (S293). This patient also carried a
t(8;21) (q22;q22) chromosomal abnormality. The other
case involved a type ‘A’ mutation; a 4-base pair insertion
at position nucleotide 960 (Table 1). In our study, there
was no significant difference in the frequency of the
NPM1 mutations in the AML cases with a normal kar-
yotype (7.7%) compared to cases with abnormal karyo-
type (8.3%). Of note, a normal karyotype was detected
in 13/25 (52%) of the AML cases.
Analysis of NPM1 mutations compared to FLT3 and
RAS mutations
All cases were analyzed for FLT3/ITD and FLT3/AL
mutations, whereas only the two NPM1 mutant cases
were screened for NRAS, KRAS and HRAS mutations.
No common RAS mutations among the NPM1-mutated
cases were observed. Overall, FLT3/ITD mutations were
found in 3/25 (12%) of AML patients (2/3 newly diag-
nosed). Of these, 1 patient also had an NPM1 mutation.
No FLT3/AL mutations were detected.
EFS & OS
The EFS and OS at 5-years were estimated at 55.55%
(SE ± 3.25%) (Figure 1) and 61.70% (SE ± 4.1%), respec-
tively. Comparison between the NPM1-mutated group
and the NPM1-wild type group was not feasible, since
the NPM1 mutated group was composed of only 2
cases, one of which was newly diagnosed.
Discussion
The current study attempted to assess the incidence and
prognostic relevance of NPM1 mutations in childhood
AML. NPM1 mutations were found in patients with de
novo AML M1 and M2 subtypes. No mutations were
observed in patients with AML M5 FAB subtypes,
which comprised the larger group in this study. Previous
studies in childhood AML also suggested absence of
NPM1 mutations in M5 cases [2,16]. In concurrence
with other reports [1,4,7], there was no significant asso-
ciation between NPM1 mutations and sex, high WBC or
increased blast percentage in the bone marrow at
diagnosis.
NPM1 mutations were found in patients above 3 years
of age. This is in agreement with previous studies that
have also demonstrated a trend towards higher probabil-
ity of NPM1 mutations for older AML pediatric patients
[1,4,17]. Rau and Brown [17] proposed the possibility of
a relative myeloid progenitor cell resistance to NPM1
mutations in younger pediatric patients.
In our study, t(8;21)(q22;q22) was observed in 16% of
the total AML cases and in 33.3% of the cases bearing a
chromosomal aberration. NPM1 mutations were
observed in one M2 AML case bearing a t(8;21)(q22;
q22). Previous studies suggested that in AML, especially
in the M2 subtype, translocation t(8;21)(q22;q22) is one
of the most frequent chromosomal abnormalities and
can be found in 5-12% of AML cases [18].
Frequently, translocations involving chromosome
11q23 can be found in 15-20% of pediatric AML cases
and are, in general, associated with a poor outcome
[19]. In line with other work [1], our study demon-
strated that translocations involving MLL gene rearran-
gements with chromosome 11q23 abnormality occurred
in 12% of patients and was more common in children
younger than 3 years of age (66.6%).
Progression of MDS to AML may represent a similar,
though, more complicated model for leukemic transfor-
mation [20]. In the current study, no NPM1 mutations
were detected in cases with secondary AML following
MDS, which is in line with previous studies associating
absence or low rates of NPM1 mutations in patients
with MDS [10,21].
Mutations of the NPM1 gene were present in 8% of
AML cases in this study. This is in agreement with pre-
vious reports on childhood AML [1,4,17]. More than 40
different types of NPM1 mutations have been detected,
with types A, B and D being the most common [7]. In
our study, sequencing analysis confirmed the presence of
at y p e‘A’ mutation in one NPM1-mutated case. The
majority of NPM1 mutations encode mutant proteins
that have a novel nuclear export signal (NES) motif
inserted at the C-terminus and are thought to play a sig-
nificant role in the abnormal cytoplasmic localization of
the NPM protein. The other mutation obtained in the
present study, involved 2 individual base pair substitu-
tions which resulted in 2 amino acid changes (W290)
Table 1 Patients’ molecular and clinical characteristics
Patient
No.
Nucleotide sequences Sex Age
(years)
FAB
Type
Karyotype MLL
rearrangement
FLT3
mutation
WBC Blast Count
in BM (%)
Survival
Wild
type
gat ctc tgg cag tgg agg aag tct ctt taa gaa aat ag
1 gat ctc tgt ctggca gtg gag gaa
gtc tct tta aga aaa tag
M 8 years M1 46, xy N None 23900 85% Complete
Remission
2 gat ctc tgg cag ggg agg aag cct
ctt taa gaa aat ag
F1 3
years
M2 46, xx t(8;21)
(q22;q22)
N FLT3/ITD 7680 60% Complete
Remission
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a novel mutation, even though disruption of the nucleo-
lar localization signal (NLS) at C-terminus due to muta-
tions in the tryptophan residue 290 has been previously
described [17]. More specifically, the tryptophan residue
at position 290 is considered essential to the nucleolar
localization of the NPM protein [2], however, the overall
impact of the presence of both amino acid changes that
were detected in our study, remains undefined.
FLT3 gene mutations were identified in 12% of the
total AML cases. This is in line with other studies, in
which 11.5% of the cases carried an ITD mutation in
the FLT3 gene [4]. FLT3/ITD mutation was observed
in one NPM1-mutated case bearing t(8;21) (q22;q22). It
is not feasible to predict the prognostic value of both
mutations in the presence of this translocation, since
the time this patient has been monitored is rather short.
Rau and Brown [17] and Boonthimat et al. [22] sug-
gested a principal prevalence of FLT3/ITD mutations in
NPM1-mutated cases, due to a possible pathogenic link
between these two gene mutations.
No correlation was found between RAS mutations and
the frequency of NPM1 mutations. This was similarly
observed by Boonthimat et al. [22] who suggested that
NPM1 and RAS do not cooperate in the pathogenic
model of AML. Of note, NRAS mutations are normally
found in AML cases with inv(16), which are essentially
mutually exclusive of NPM1 mutations [23].
To conclude, it seems that NPM1 mutations are con-
sistently present in approximately 10% of childhood
AML cases [17]. However the observation of a high vari-
ety of NPM1 mutations merits further studies, in order
to determine their individual contribution to the patho-
genesis of childhood AML and their comprehensible
relation to prognosis.
Acknowledgements
The authors would like to thank Dr. Alexandra L. Perry for editing the
manuscript and Mr. George Barakos for assistance with statistical analysis.
Author details
1University Research Institute for the Study and Treatment of Childhood
Genetic and Malignant Diseases, University of Athens, “Aghia Sophia”
Children’s Hospital, Athens, Greece.
2Hematology/Oncology Unit, First
Department of Pediatrics, University of Athens, “Aghia Sophia” Children’s
Hospital, Athens, Greece.
Authors’ contributions
MB organized the research plan, analyzed data, performed experiments and
drafted the paper. CP and KK, carried out part of the experiments. TN and
KK provided samples and clinical data and F.T-S coordinated the study,
participated in its design and contributed to writing. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 24 August 2010 Accepted: 27 October 2010
Published: 27 October 2010
References
1. Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G, Alonzo TA,
Chang M, Arceci RJ, Small D: The incidence and clinical significance of
nucleophosmin mutations in childhood AML. Blood 2007, 110:979-985.
2. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G:
Prevalence and prognostic impact of NPM1 mutations in 1485 adult
patients with acute myeloid leukemia. Blood 2006, 107:4011-4020.
3. Ahmad F, Mandava S, Das BR: Mutations of NPM1 gene in de novo acute
myeloid leukemia: determination of incidence, distribution pattern of
two novel mutations in Indian population. Hematol Oncol 2009, 27:90-97.
4. Cazzaniga G, Dell’Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V, Locatelli F,
Martelli MF, Basso G, Pession A, Biondi A, Falini B: Nucleophosmin
mutations in childhood acute myelogenous leukemia with normal
karyotype. Blood 2005, 106:1419-1422.
5. Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, Kodera Y,
Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H,
Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T,
Emi N, Naoe T: Clinical Characteristics and prognostic implications of
NPM1 mutations in acute myeloid leukemia. Blood 2005, 106:2854-2861.
6. Jeong EG, Lee SH, Yoo NJ, Lee SH: Absence of nucleophosmin 1 (NPM1)
gene mutations in common solid cancers. APMIS 2005, 115:341-346.
7. Ruan GR, Li JL, Qin YZ, Li LD, Xie M, Chang Y, Zhang Y, Liu YR, Jiang B,
Chen SS, Huang XJ: Nucleophosmin mutations in Chinese adults in acute
myelogenous leukemia. Ann Hematol 2009, 88:159-166.
8. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R,
Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A,
Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F,
Pelicci PG, Martelli MF, GIMEMA Acute Leukemia Working Party:
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a
normal karyotype. N Engl J Med 2005, 352:254-266.
9. Chou WC, Tang JL, Lin LI, Yao M, Tsay W, Chen CY, Wu SJ, Huang CF,
Chiou RJ, Tseng MH, Lin DT, Lin KH, Chen YC, Tien HF: Nucleophosmin
Figure 1 Kaplan and Meier Survival curve.
Braoudaki et al. Journal of Hematology & Oncology 2010, 3:41
http://www.jhoonline.org/content/3/1/41
Page 4 of 5mutations in de novo acute myeloid leukemia: The age-dependent
indices and the stability during disease evolution. Cancer Res 2006,
66:3310-3316.
10. Zhang Y, Zhang M, Yang L, Xiao Z: NPM1 mutations in myelodysplastic
syndromes and acute myeloid leukemia with normal karyotype. Leuk Res
2007, 31:109-111.
11. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF,
Haferlach T, Hiddemann W, Falini B: Nucleophosmin gene mutations are
predictors of favorable prognosis in acute myelogenous leukemia with a
normal karyotype. Blood 2005, 106:3733-3739.
12. Syampurnawati M, Tatsumi E, Ardianto B, Takenokuchi M, Nakamachi Y,
Kawano S, Kumagai S, Saigo K, Matsui T, Takahashi T, Nagai K, Gunadi ,
Nishio H, Yabe H, Kondo S, Hayashi Y: DR negativity is a distinctive
feature of M1/M2 AML cases with NPM1 mutation. Leuk Res 2008,
32:1141-1143.
13. Stirewalt DL, Radich JP: The role of FLT3 in hematopoietic malignancies.
Nat Rev Cancer 2003, 3:650-665.
14. Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A,
Bullinger L, Fröhling S, Döhner H: Mutant nucleophosmin (NPM1) predicts
favorable diagnosis in younger adults with acure myeloid leukemia and
normal cytogenetics: interaction with other gene mutations. Blood 2005,
106:3740-3746.
15. Braoudaki M, Karpusas M, Katsibardi K, Papathanassiou Ch, Karamolegou K,
Tzortzatou-Stathopoulou F: Frequency of FLT3 mutations in childhood
acute lymphoblastic leukemia. Med Oncol 2009, 26:460-462.
16. Thiede C, Creutzig E, Reinhardt D, Ehninger G, Creutzig U: Different types
of NPM1 mutations in children and adults: evidence for an effect of
patient age on the prevalence of TCTG-tandem duplication in NPM1-
exon 12. Leukemia 2007, 21:366-367.
17. Rau R, Brown P: Nucleophosmin (NPM1) mutations in adult and
childhood acute myeloid leukemia: towards definition of a new
leukemia entity. Hematol Oncol 2009, 27:171-181.
18. Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE,
van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH,
Pandolfi PP, Hiebert SW: The t(8;21) fusion protein, AML1 ETO, specifically
represses the transcription of the p14(ARF) tumor suppressor in acute
myeloid leukemia. Nat Med 2002, 8:743-750.
19. Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Gresik MV, Steuber CP,
Weinstein HJ, Carroll AJ: Chromosomal abnormalities in 478 children with
acute myeloid leukemia: clinical characteristics and treatment outcome
in a cooperative pediatric oncology group study-POG 8821. Blood 1999,
94:3707-3716.
20. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C: Genetic
pathways in therapy-related myelodysplasia and acute myeloid
leukemia. Blood 2002, 99:1909-1912.
21. Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, Kondo T, Kuroiwa H,
Okada M, Mori N, Motoji T: Lack of nucleophosmin mutation in patients
with myelodysplastic syndrome and acute myeloid leukemia with
chromosome 5 abnormalities. Leuk Lymphoma 2007, 48:2141-2144.
22. Boonthimat C, Thongnoppakhun W, Auewarakul CU: Nucleophosmin
mutation in the Southeast Asian acute myeloid leukemia: eight novel
variants, FLT3 coexistance and prognostic impact of NPM1/FLT3
mutations. Hematologica 2008, 93:1565-1569.
23. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, et al:
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML):
association with other abnormalities and previously established gene
expression signatures and their favorable prognostic significance. Blood
2005, 106:3747-3754.
doi:10.1186/1756-8722-3-41
Cite this article as: Braoudaki et al.: The frequency of NPM1 mutations in
childhood acute myeloid leukemia. Journal of Hematology & Oncology
2010 3:41.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Braoudaki et al. Journal of Hematology & Oncology 2010, 3:41
http://www.jhoonline.org/content/3/1/41
Page 5 of 5